3-(1H-pyrazol-4-yl)pyridine allosteric modulators of the M4 muscarinic acetylcholine receptor

US11970479B2 · kind B2 · utility

Assignees

• Merck Sharp & Dohme LLC · US
• MSD R&D (China) Co. Ltd. · CN

Inventors

• John J. Acton, III · Cranford, US
• Melissa Egbertson · Ambler, US
• Xiaolei Gao · Bound Brook, US
• Scott T. Harrison · Cheltenham, US
• Timothy J. Henderson · Natick, US
• Michael Man-Chu Lo · Rahway, US
• Robert Mazzola · Stewartsville, US
• Zhaoyang Meng · Ambler, US
• James Mulhearn · Cheltenham, US
• Vanessa L. Rada · Hatfield, US
• Jeffrey W. Schubert · Ambler, US
• Oleg B. Selyutin · Princeton Colonial Park, US
• David M. Tellers · Lansdale, US
• Ling Tong · Hackettstown, US
• Fengqi Zhang · Gaorihan, CN
• Jianming Bao · Scotch Plains, US
• Chunsing Li · Shanghai, CN

Key dates

• Filing date: Oct 24, 2019
• Grant date: Apr 30, 2024
• Expiry date: Dec 19, 2040

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D471/04
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

The present invention is directed to cinnolinyl and quinolinyl pyrazol-4-yl-pyridine compounds which are allosteric modulators of the M4 muscarinic acetylcholine receptor. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which M4 muscarinic acetylcholine receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which M4 muscarinic acetylcholine receptors are involved.